Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice
Clinical and Experimental Vaccine Research
;
: 58-65, 2013.
Article
in English
| WPRIM
| ID: wpr-195042
ABSTRACT
PURPOSE:
A pep27 mutant may be able to elicit mucosal immunity against pneumococcal diseases, and could be employed as an inexpensive attenuated vaccine. However, this particular mutant contains an erythromycin-resistance marker. The purpose of the current study is to develop a markerless pep27 mutant and assess whether this inactivated mutant is able to induce mucosal immunity. MATERIALS ANDMETHODS:
Mice were vaccinated intranasally with the inactivated markerless pep27 mutant every 2 weeks for a total of three times, after which time serum samples were analyzed for antibody titers. The mice were then challenged with a lethal D39 strain and their survival time was measured. The cross-reactivity of the antisera against pep27 was also compared to other mutant serotypes.RESULTS:
Intranasal immunization of mice with the inactivated markerless pep27 mutant provides effective protection and rapidly cleared bacterial colonization in vivo. Moreover, antisera raised against the pep27 mutant may cross-react with several other serotype strains.CONCLUSION:
Intranasal immunization with the inactivated pep27 mutant may be able to provide mucosal immunity, and could represent an efficient mucosal vaccine.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sprains and Strains
/
Streptococcus pneumoniae
/
Immunization
/
Colon
/
Immunity, Mucosal
/
Immune Sera
Limits:
Animals
Language:
English
Journal:
Clinical and Experimental Vaccine Research
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS